BriaCell presents data from Phase 2 study of Bria-IMT

BriaCell (BCTX) Therapeutics is presenting positive data from its Phase 2 study of lead product candidate, Bria-IMT, in metastatic breast cancer, and from its preclinical Bria-OTS+ platform at the 2025 American Association for Cancer Research, AACR, Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. In addition, Phase 3 early biomarker data will be presented as a late breaking abstract. Patients have been heavily pre-treated a median of 6 prior treatments — including Antibody-Drug Conjugates and check point inhibitors: Clinical benefit rates ranged from 45% to 100% based on subtype; Decrease in size or no change in all tumors noted in 83% of patients receiving Phase 3 formulation; Overall survival with the Phase 3 formulation was 17.3 months for HR+ patients and 11.44 months for patients with triple negative breast cancer; Overall response rate for patients with intracranial metastases was 50% with a 75% clinical benefit rate; Safety profile: No unexpected adverse events, no treatment related discontinuation of therapy